Generic Name and Formulations:
Hepatitis A vaccine, inactivated 720 ELISA Units (EL.U.) per 0.5mL (pediatric), or 1440 EL.U. per 1mL (adult); susp for IM inj; aluminum adsorbed; contains neomycin (trace); preservative-free.
Indications for HAVRIX:
Hepatitis A immunization.
Inject into deltoid, preferably at least 2 weeks before expected exposure. >18yrs: 1440 EL.U. once IM; give booster dose 6–12 months after initial course.
Inject IM preferably at least 2 weeks before expected exposure. <12months: not recommended. 12months–18yrs: 720 EL.U. once IM; give booster dose 6–12months after initial course.
Neomycin allergy. Previous hypersensitivity reaction to hepatitis A-containing vaccine.
Have epinephrine (1:1000) inj available. Fever. Bleeding disorders. Immunodeficiency (may have suboptimal response). If given with immune globulin, use separate syringe and different site. Latex allergy. Pregnancy (Cat.C). Nursing mothers.
Immunosuppressives may reduce efficacy. Concomitant vaccines: see literature.
Inj site reactions, headache, fatigue, fever, malaise, anorexia, GI upset.
Single-dose vials—10; Single-dose prefilled Tip-Lok syringes—5 (without needles)
Neurology Advisor Articles
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- Smoking Promotes Disease Progression in Multiple Sclerosis
- Situation Framing, Language Can Influence Decision-Making
- Thrombolysis With Tenecteplase Is as Safe as Alteplase in Stroke Mimics
- FDA: Opioid Analgesic REMS Expanded to Include Immediate-Release Products